Edwin Smith papyrus case 8.

J Neurosurg

Tucson, AZ; and 

Published: September 2014

Download full-text PDF

Source
http://dx.doi.org/10.3171/2014.5.JNS141078DOI Listing

Publication Analysis

Top Keywords

edwin smith
4
smith papyrus
4
papyrus case
4
edwin
1
papyrus
1
case
1

Similar Publications

Congenital melanocytic nevi are present at birth or develop within the first few months of life. Giant congenital melanocytic nevi are a rare variant and may involve the external genitalia with a confluent "bathing trunk" distribution. Rapid growth of proliferative nodules of melanocytic cells may cause disfigurement and anatomical distortion resulting in psychological distress and loss of functionality.

View Article and Find Full Text PDF

Background: Management patterns and outcomes are poorly defined in cases of late PUV diagnosis.

Objective: To compare post-ablation management and clinical outcomes of patients with infantile (<1 year) versus childhood (>5 year) PUV diagnosis to gain insight into the pathologies at opposite ends of the PUV spectrum.

Study Design: A multicenter retrospective cohort study was conducted using the TriNetX research network between 2006 and 2022.

View Article and Find Full Text PDF

Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric Patient With Bladder Rhabdomyosarcoma: A Case Report.

Urology

November 2023

Pediatric Urology Department, Emory University School of Medicine, Sandy Springs, GA; Pediatric Urology Department, Children's Healthcare of Atlanta, Atlanta, GA. Electronic address:

Rhabdomyosarcoma (RMS) treatment involves surgery, chemotherapy, and radiotherapy. A radioprotective space between the bladder/prostate and rectum reduces postradiation complications, as reported in adult patients. Describe pediatric preradiotherapy perirectal hyaluronic acid (HA) spacer injection for bladder/prostate RMS.

View Article and Find Full Text PDF

Objective: This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Methods: A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background treatments, including immunosuppressive therapies (IST).

Results: The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!